Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8602-8613

  Goldshmit, Yona ^a,b   Trangle, Sari Schokoroy ^a   Kloog, Yoel ^a   Pinkas Kramarski, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b MONASH UNIVERSITY   (Australia)

Author keywords

AS1411; ErbB1; FTS; Nucleolin; Ras; Signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; AS 1411; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOLIN; PROTEIN KINASE B; RAS PROTEIN; SALIRASIB; UNCLASSIFIED DRUG; AGRO 100; EGFR PROTEIN, HUMAN; FARNESOL; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHOPROTEIN; RNA BINDING PROTEIN; SALICYLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL DEATH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CELL MOTION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FARNESOL; GLIOBLASTOMA; HUMANS; MICE, NUDE; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; RAS PROTEINS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA-BINDING PROTEINS; SALICYLATES; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR BURDEN;

EID: 84908006508     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2343     Document Type: Article

References (42)

1. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K and Delattre JY. Primary brain tumours in adults. Lancet. 2012; 379(9830):1984-1996.
2. Huang PH, Xu AM and White FM. Oncogenic EGFR signaling networks in glioma. Science signaling. 2009; 2(87):re6.
3. Vojtek AB and Der CJ. Increasing complexity of the Ras signaling pathway. The Journal of biological chemistry. 1998; 273(32):19925-19928.
4. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Current opinion in cell biology. 1998; 10(2):262-267.
5. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev. 1998; 8(1):49-54.
6. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB and Biegel JA. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol. 2010; 12(7):621-630.
7. Aharonson Z, Gana-Weisz M, Varsano T, Haklai R, Marciano D and Kloog Y. Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta. 1998; 1406(1):40-50.
8. Bates PJ, Kahlon JB, Thomas SD, Trent JO and Miller DM. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. The Journal of biological chemistry. 1999; 274(37):26369-26377.
9. Srivastava M and Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J. 1999; 13:1911-1922.
10. Storck S, Thiry M and Bouvet P. Conditional knockout of nucleolin in DT40 cells reveals the functional redundancy of its RNA binding domains. Biol Cell. 2008.
11. Ugrinova I, Monier K, Ivaldi C, Thiry M, Storck S, Mongelard F and Bouvet P. Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol. 2007; 8:66.
12. Legrand D, Vigie K, Said E, Elass E, Masson M, Slomianny M, Carpentier M, Briand J, Mazurier J and Hovanessian A. Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem. 2004; 271:303-317.
13. Stepanova V, Lebedeva T, Kuo A, Yarovoi S, Tkachuk S, Zaitsev S, Bdeir K, Dumler I, Marks MS, Parfyonova Y, Tkachuk VA, Higazi AA and Cines DB. Nuclear translocation of urokinase-type plasminogen activator. Blood. 2008; 112(1):100-110.
14. Derenzini M, Sirri V, Trere D and Ochs RL. The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Laboratory investigation; a journal of technical methods and pathology. 1995; 73(4):497-502.
15. Galzio R, Rosati F, Benedetti E, Cristiano L, Aldi S, Mei S, D'Angelo B, Gentile R, Laurenti G, Cifone MG, Giordano A and Cimini A. Glycosilated nucleolin as marker for human gliomas. Journal of cellular biochemistry. 2012; 113(2):571-579.
16. Hovanessian AG, Soundaramourty C, El Khoury D, Nondier I, Svab J and Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PloS one. 2010; 5(12):e15787.
17. Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, Guichard G, Briand JP, Courty J and Hovanessian AG. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PloS one. 2008; 3(6):e2518.
18. Teng Y, Girvan AC, Casson LK, Pierce WM, Jr., Qian M, Thomas SD and Bates PJ. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer research. 2007; 67(21):10491-10500.
19. Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, Trent JO, Miller DM and Bates PJ. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. The Journal of biological chemistry. 2001; 276(46):43221-43230.
20. Di Segni A, Farin K and Pinkas-Kramarski R. Identification of nucleolin as new ErbB receptors-interacting protein. PloS one. 2008; 3(6):e2310.
21. Farin K and Pinkas-Kramarski R. The crosstalk between ErbB1 and nucleolin. . Communicative & Integrative Biology 2009; 2(6):523-525.
22. Farin K, Schokoroy S, Haklai R, Cohen-Or I, Elad-Sfadia G, Reyes-Reyes ME, Bates PJ, Cox AD, Kloog Y and Pinkas-Kramarski R. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. Cancer research. 2011; 71(6):2140-2151.
23. Farin K, Di Segni A, Mor A and Pinkas-Kramarski R. Structure-function analysis of nucleolin and ErbB receptors interactions. PloS one. 2009; 4(7):e6128.
24. Schokoroy S, Juster D, Kloog Y and Pinkas-Kramarski R. Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death. PloS one. 2013; 8(9):e75269.
25. Cox AD and Der CJ. Farnesyltransferase inhibitors: promises and realities. Current opinion in pharmacology. 2002; 2(4):388-393.
26. Bar M, Aharon M, Benjamin S, Rotblat B, Horowitz M and Avni A. AtEHDs, novel Arabidopsis EH-domain-containing proteins involved in endocytosis. The Plant journal: for cell and molecular biology. 2008; 55(6):1025-1038.
27. Kloog Y and Cox AD. RAS inhibitors: potential for cancer therapeutics. Molecular medicine today. 2000; 6(10):398-402.
28. Ireson CR and Kelland LR. Discovery and development of anticancer aptamers. Molecular cancer therapeutics. 2006; 5(12):2957-2962.
29. Dapic V and Bates PJ TJ, Rodger A, Thomas SD, Miller DM. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry. 2002; 41(11):367-385.
30. Reyes-Reyes EM, Teng Y and Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer research. 2010; 70(21):8617-8629.
31. Etienne-Manneville S. In vitro assay of primary astrocyte migration as a tool to study Rho GTPase function in cell polarization. Methods in enzymology. 2006; 406:565-578.
32. Goldberg L and Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer research. 2006; 66(24):11709-11717.
33. Nagane M, Huang HJ and Cavenee WK. Advances in the molecular genetics of gliomas. Current opinion in oncology. 1997; 9(3):215-222.
34. Soni D, King JA, Kaye AH and Hovens CM. Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2005; 12(1):1-5.
35. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS and Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89(7):2965-2969.
36. Di Segni A, Ben-Baruch N and Pinkas-Kramarski R. (2009). The ErbB family of receptor tyrosine kinases:key regulators in breast cancer and other malignancies. In: Ben-Baruch A, ed. Breast cancer: From Pathogenesis to Potential therapeutic Modalities. (Kerala: Transworld Research Network), pp. 77-105.
37. Guha A, Feldkamp MM, Lau N, Boss G and Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 1997; 15(23):2755-2765.
38. Besson A and Yong VW. Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas. Journal of neuro-oncology. 2001; 51(3):245-264.
39. Breier G, Blum S, Peli J, Groot M, Wild C, Risau W and Reichmann E. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. International journal of cancer Journal international du cancer. 2002; 97(2):142-148.
40. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nature reviews Genetics. 2001; 2(2):120-129.
41. Xu Z, Joshi N, Agarwal A, Dahiya S, Bittner P, Smith E, Taylor S, Piwnica-Worms D, Weber J and Leonard JR. Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest. Journal of neuro-oncology. 2012; 108(1):59-67.
42. Haklai R, Elad-Sfadia G, Egozi Y and Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol. 2008; 61(1):89-96.